Apretude indicated for high-risk adults and adolescents over 12.
GSK revealed that ViiV Healthcare, an HIV specialist which it owns a majority of, has received authorization by the European Commission (EC) for HIV prevention treatment Apretude (cabotegravir long-acting (LA) injectable and tablets). Indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents over 12, the medication is currently the only HIV prevention option approved in the European Union that requires only six injections a year.
“This authorization marks a pivotal milestone for people across the EU who could benefit from an innovative, long-acting HIV prevention option that may better suit their personal preferences,” said Deborah Waterhouse, CEO, ViiV Healthcare, in a company press release. “Long-acting PrEP, alongside other HIV prevention strategies, plays an important role in helping to address some of the challenges that people may have with oral PrEP options”.
Reference: European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention. GSK. September 19, 2023. Accessed September 19, 2023. https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-viiv-healthcare-s-apretude/